Ipamorelin vs Vesilute
Well Studied vs Moderate Research
synergistic Mechanism-based · 47% Ipamorelin and Vesilute work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
Ipamorelin Vesilute
Weight 711.85 Da 262 Da
Half-life ~2 hours Not established
Chain 5 amino acids 2 amino acids
Type Growth hormone secretagogue Dipeptide bioregulator
Key Benefits
Ipamorelin
01 Optimal GH stimulation with superior bioavailability
02 Body composition improvements (lean mass, fat loss)
03 Enhanced recovery and anti-aging effects
04 Minimal side effects compared to other GHRPs
05 No significant cortisol or prolactin elevation
06 Improved sleep quality
Vesilute
01 Supports bladder and urinary tract function
02 May improve prostate health in men
03 Regulates smooth muscle function
04 Enhances pelvic tissue blood flow
05 Supports cellular regeneration
06 Part of comprehensive Khavinson bioregulator protocols
07 Well-tolerated in research
08 Oral bioavailability as small dipeptide
Dosing Protocols
Ipamorelin
200-300 mcg per injection / 1-3 times daily depending on goals (1x for longevity, 2-3x for performance)
General Health & Longevity 200mcg 1x daily before bed
Body Composition 250-300mcg 2x daily (morning, pre-workout)
Athletic Performance 200-250mcg 2-3x daily
Sleep & Recovery 200mcg 1x daily 30min before bed
Anti-Aging Protocol 200-250mcg 1-2x daily
Vesilute
10-20 mg per day / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Standard protocol 10-20 mg Daily for 10-20 days
Maintenance 20 mg 2-3 cycles yearly
Side Effects
Ipamorelin
Mild hunger increase 20-30 minutes post-injection
Slight drowsiness when taken before bed
Water retention (mild)
Vesilute
Generally well-tolerated
Injection site reactions (mild, if injectable)
Minimal reported side effects
Contraindications
Pregnancy or breastfeeding
Active cancer or history of cancer
Severe kidney or liver disease
Known hypersensitivity to peptide components
Active urinary tract infection (treat first)
Pregnancy or breastfeeding
Prostate cancer (consult physician)
Research Evidence
Ipamorelin Vesilute
Status Well Studied Moderate Research
References 5 studies 3 studies
Latest October 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.